These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34872474)

  • 1. Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine.
    Ray SK; Mukherjee S
    Curr Mol Med; 2022; 22(10):835-850. PubMed ID: 34872474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.
    Yeh SJ; Hsu BJ; Chen BS
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Regulation of
    Zhang H; Zhang N; Liu Y; Su P; Liang Y; Li Y; Wang X; Chen T; Song X; Sang Y; Duan Y; Zhang J; Wang L; Chen B; Zhao W; Guo H; Liu Z; Hu G; Yang Q
    Cancer Res; 2019 Jul; 79(13):3347-3359. PubMed ID: 30940661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
    DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
    Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
    Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
    Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
    Qattan A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer.
    Chen C; Gao D; Huo J; Qu R; Guo Y; Hu X; Luo L
    Sci Rep; 2021 Jun; 11(1):12172. PubMed ID: 34108519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
    Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics.
    Mandumpala JJ; Baby S; Tom AA; Godugu C; Shankaraiah N
    Life Sci; 2022 Mar; 292():120321. PubMed ID: 35031259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling.
    Vishnubalaji R; Alajez NM
    Sci Rep; 2021 Jul; 11(1):15410. PubMed ID: 34326372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review.
    Muhammad A; Forcados GE; Katsayal BS; Bako RS; Aminu S; Sadiq IZ; Abubakar MB; Yusuf AP; Malami I; Faruk M; Ibrahim S; Pase PA; Ahmed S; Abubakar IB; Abubakar M; Yates C
    Epigenomics; 2022 Jun; 14(11):711-726. PubMed ID: 35473304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
    Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer.
    Ding L; Gu H; Xiong X; Ao H; Cao J; Lin W; Yu M; Lin J; Cui Q
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress of non-coding RNAs in triple-negative breast cancer.
    Liu J; Zhao G; Liu XL; Zhang G; Zhao SQ; Zhang SL; Luo LH; Yin DC; Zhang CY
    Life Sci; 2021 May; 272():119238. PubMed ID: 33600860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
    Zhou L; Yu CW
    Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic features of rapid versus late relapse in triple negative breast cancer.
    Zhang Y; Asad S; Weber Z; Tallman D; Nock W; Wyse M; Bey JF; Dean KL; Adams EJ; Stockard S; Singh J; Winer EP; Lin NU; Jiang YZ; Ma D; Wang P; Shi L; Huang W; Shao ZM; Cherian M; Lustberg MB; Ramaswamy B; Sardesai S; VanDeusen J; Williams N; Wesolowski R; Obeng-Gyasi S; Sizemore GM; Sizemore ST; Verschraegen C; Stover DG
    BMC Cancer; 2021 May; 21(1):568. PubMed ID: 34006255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Pathophysiology of Triple-Negative Breast Cancer: The Potential of lncRNAs for Clinical Diagnosis, Treatment, and Prognostic Monitoring.
    Zhou Y; Yue Y; Fan S; Jia Q; Ding X
    Mol Biotechnol; 2021 Dec; 63(12):1093-1102. PubMed ID: 34245439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.